Alimentiv Inc.

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants with Permanent Ileostomy

Not yet recruiting

Conditions: Crohns Disease

First Posted Date: 2024-11-01

Last Posted Date: 2024-11-04

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 50

Registration Number: NCT06670638

VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Phase 4

Recruiting

Conditions: Crohn Disease
Moderately to Severely Active Crohn's Disease
Disease Crohn

Interventions: Biological: Vedolizumab

First Posted Date: 2024-02-14

Last Posted Date: 2024-08-14

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 304

Registration Number: NCT06257706

Locations: 🇩🇪
Universitaetsklinikum Schleswig-Holstein (UKSH)- Campus Kiel, Kiel, Schleswig-Holstein, Germany
🇦🇺
South Metropolitan Health Service, Murdoch, Western Australia, Australia
🇨🇦
Toronto Immune and Digestive Health Institute Inc. (TIDHI), Toronto, Ontario, Canada

and more 33 locations

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

Recruiting

Conditions: Crohn's Disease

Interventions: Drug: Vedolizumab (VDZ)
Drug: Ustekinumab (UST)
Drug: Risankizumab (RISA)

First Posted Date: 2024-02-08

Last Posted Date: 2024-10-28

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 300

Registration Number: NCT06249555

Locations: 🇺🇸
Digestive and Liver Center of Florida, Kissimmee, Florida, United States
🇺🇸
Northwestern University, Evanston, Illinois, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States

and more 9 locations

Assessment of Patients With Acute Pouchitis Treated With Antibiotics

Suspended

Conditions: Pouchitis
Ulcerative Colitis

Interventions: Other: Observational, No intervention

First Posted Date: 2022-02-23

Last Posted Date: 2024-02-20

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 43

Registration Number: NCT05252273

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇳🇱
Academic Medical Center Amsterdam., Amsterdam, Netherlands
🇨🇦
Toronto Immune and Digestive Health Institute (TIDHI)., Toronto, Ontario, Canada

and more 1 locations

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Janus Kinase Inhibitor

First Posted Date: 2020-10-05

Last Posted Date: 2022-01-04

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 3

Registration Number: NCT04576000

Locations: 🇳🇱
Amsterdam Medical Center, IBD Center, Amsterdam, North Halland, Netherlands

Determination of the Optimal Treatment Target in Ulcerative Colitis

Phase 4

Active, not recruiting

Conditions: Colitis, Ulcerative

Interventions: Biological: Treatment Algorithm A
Biological: Treatment Algorithm B
Biological: Treatment Algorithm C

First Posted Date: 2020-02-06

Last Posted Date: 2024-06-13

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 672

Registration Number: NCT04259138

Locations: 🇨🇦
LHSC - Victoria Hospital, London, Ontario, Canada
🇵🇱
Sonomed Sp. z o.o. - Centrum Medyczne, Szczecin, West Pomeranian, Poland
🇺🇦
Ternopil City Communal Emergency Medical Care Hosp, Ternopil, Ukraine

and more 55 locations

Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: Infliximab

First Posted Date: 2018-12-05

Last Posted Date: 2024-05-08

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 18

Registration Number: NCT03765450

Locations: 🇺🇸
Cornell University, New York, New York, United States
🇺🇸
UCSD, San Diego, California, United States
🇨🇦
London Health Sciences Center, London, Ontario, Canada

and more 1 locations

Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

Phase 4

Active, not recruiting

Conditions: Crohn Disease
Remission

Interventions: Other: 5-ASA Withdrawal

First Posted Date: 2017-08-24

Last Posted Date: 2024-05-08

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 334

Registration Number: NCT03261206

Locations: 🇺🇦
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
🇺🇦
Vinnytsia Nation Medical University N.I. Pirogov, Vinnytsia, Ukraine
🇬🇧
Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon, Essex, United Kingdom

and more 39 locations

Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Phase 2

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: MTX 25
Drug: Adalimumab
Drug: MTX 12.5

First Posted Date: 2012-10-29

Last Posted Date: 2021-06-23

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 22

Registration Number: NCT01716039

Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy

Phase 4

Completed

Conditions: Crohn's Disease

Interventions: Other: Conventional Step-care Algorithm
Other: Enhanced Treatment Algorithm

First Posted Date: 2012-10-02

Last Posted Date: 2021-11-11

Lead Sponsor: Alimentiv Inc.

Target Recruit Count: 1095

Registration Number: NCT01698307

Locations: 🇨🇦
Oravec Medicine Professional Corporation, Oshawa, Ontario, Canada
🇺🇸
Louisiana Research Center, LLC, Shreveport, Louisiana, United States
🇺🇸
Asheville Gastroenterology Associates, PA, Asheville, North Carolina, United States

and more 19 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy